Possible Side Effects of Growth Hormone in Children with GHD
Growth hormone therapy in children with growth hormone deficiency is generally safe, but clinicians must monitor for specific adverse effects including intracranial hypertension, slipped capital femoral epiphysis, glucose intolerance, and accelerated bone maturation. 1
Common and Serious Side Effects
Musculoskeletal Complications
Slipped capital femoral epiphysis (SCFE) represents one of the most serious orthopedic complications requiring immediate attention. Children with GHD are inherently prone to SCFE both before and during GH treatment 1, 2. GH therapy must be discontinued immediately if SCFE is confirmed 1. Any child presenting with limping or complaints of hip or knee pain requires urgent bone radiographs to rule out this complication 1.
Intracranial Hypertension
Benign intracranial hypertension can occur during the first 8-12 weeks after initiating GH treatment 2. This is particularly relevant in children with GHD, Turner syndrome, or renal insufficiency 2. Treatment must be stopped if intracranial hypertension develops 1. This side effect, while rare, is more common in children than adults receiving GH therapy 2.
Metabolic Effects
Glucose intolerance and insulin resistance can develop during GH treatment 1, 3, 4. Regular monitoring of serum glucose levels is recommended every 3-6 months 1. The diabetogenic effect of GH occurs through inhibition of glucose utilization, though clinically significant diabetes remains uncommon in pediatric patients 5.
Endocrine Monitoring Requirements
Thyroid function requires surveillance as GH can unmask central hypothyroidism. Monitor TSH and free T3 levels every 3-6 months 1. This is critical because untreated hypothyroidism will blunt the growth response to GH therapy.
Skeletal Maturation
While no strong evidence supports accelerated pubertal development with GH therapy, anecdotal reports exist 1. Annual assessment of pubertal stages (Tanner staging) is recommended for children older than 10 years 1. Accelerated bone maturation is a potential indication to stop GH treatment 1.
Less Common Side Effects
Local and Systemic Reactions
Fluid Retention
Peripheral edema can occur but is far less common in children than adults 2. Sodium and water retention may develop occasionally 3. Unlike adult patients, carpal tunnel syndrome is rare in pediatric populations 2.
Scoliosis
Progression of pre-existing scoliosis may occur during treatment 3, 4. Baseline assessment and monitoring of spinal curvature is prudent in at-risk patients.
Critical Safety Considerations
Absolute Contraindications for Stopping GH
Treatment must be discontinued in the following scenarios 1:
- Epiphyseal closure (growth plates closed)
- Occurrence of intracranial hypertension
- Confirmed slipped capital femoral epiphysis
- Persistent severe secondary hyperparathyroidism (PTH >500 pg/ml)
- Unexplained decrease in renal function (in CKD patients)
- Active malignancy
Monitoring Protocol
Clinic visits every 3-6 months should assess 1:
- Height velocity and pubertal development
- Bone age via wrist radiography
- Thyroid function (TSH, free T3)
- Glucose metabolism
- Calcium, phosphate, bicarbonate levels
- Parathyroid hormone (in CKD patients)
Long-Term Safety Profile
The overall safety profile after more than three decades of use is largely reassuring 6. Data from over 38,000 treated children show that adverse effects are relatively uncommon 2. Most treatment-emergent adverse events are mild to moderate in severity, with discontinuation due to side effects being rare 7.
Cancer Risk
While GH stimulates cell multiplication, raising theoretical concerns about neoplasm development 4, long-term surveillance data have not demonstrated increased cancer risk in appropriately selected patients without pre-existing malignancy 6.
Practical Clinical Approach
Before initiating therapy, counsel families that:
- Daily subcutaneous injections are required (typically in the evening) 1
- Most side effects are rare and manageable
- Regular monitoring is essential for safety
- Children aged 8-10 years can learn self-injection with proper training 1
During treatment, maintain vigilance for:
- Hip or knee pain (SCFE warning sign)
- Headaches with visual changes (intracranial hypertension)
- Signs of glucose intolerance
- Adequate growth response (if <2 cm/year increase over baseline, assess adherence and dosing) 1
The benefit-to-risk ratio remains favorable when GH is used appropriately in confirmed GHD, with careful patient selection and systematic monitoring protocols 1, 6.